Companies · Pharmaceuticals
WEST CHESTER · Pharmaceuticals
Diligence memoA one-page analyst read on Bpv-1 Llc — recommendation, valuation, rhythm, risks.→Bpv-1 Llc looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Bpv-1 Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Bpv-1 Llc is one of 1613 Pharmaceuticals companies tracked from WEST CHESTER. By capital raised it ranks in the long tail (ahead of 28% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 28% of sector peers (real $). Modeled value above 50% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #17 of 49.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Wiesman Capital & Co., LLC | Seed | $4.0M | $152.2M | 2.67× |
| Curzion Pharmaceuticals, Inc. | Seed | $3.5M | $133.1M | 2.33× |
| Providence Therapeutics Inc. | Seed | $8.1M | $132.2M | 2.32× |
| EnBiotix, Inc. | Seed | $6.6M | $131.8M | 2.31× |
| Metuchen Pharmaceuticals, LLC | Seed | $3.1M | $119.2M | 2.09× |
| VasoRx, Inc. | Seed | $4.7M | $117.9M | 2.07× |
| Amplicore Inc. | Seed | $2.8M | $107.1M | 1.88× |
| Lamassu Pharma, LLC | Seed | $2.7M | $101.5M | 1.78× |
| Apertor Pharmaceuticals, Inc. | Seed | $3.0M | $95.3M | 1.67× |
| Elgia Therapeutics, Inc. | Seed | $2.3M | $88.6M | 1.55× |
| Pharmapotheca A, LLC | Seed | $3.1M | $87.3M | 1.53× |
| ImmunoRx Pharma, Inc. | Seed | $2.7M | $82.2M | 1.44× |
| Bpv-1 Llc this company | Seed | $2.0M | $76.1M | 1.33× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $2.0M | 2019-07-01 | $10.0M | $76.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Brian Anderson | — | 6 other | 2019-07 |
| Gregory Doll | — | — | 2019-07 |
| Gregory Schuster | — | — | 2019-07 |
Bpv-1 Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Capitol Wellness Solutions LLC | Pharmaceuticals | Seed | $2.0M | $76.1M | same sector · same stage |
| LGM Holdings, LLC | Pharmaceuticals | Seed | $2.0M | $35.3M | same sector · same stage |
| Neurotez Inc. | Pharmaceuticals | Seed | $2.0M | $76.1M | same sector · same stage |
| PhytoCeutica, Inc. | Pharmaceuticals | Seed | $2.0M | $76.1M | same sector · same stage |
| Rundle Research LLC | Pharmaceuticals | Seed | $2.0M | $76.1M | same sector · same stage |
| Stromedix Inc | Pharmaceuticals | Seed | $2.0M | $76.1M | same sector · same stage |
| Biomerica Inc | Pharmaceuticals | Seed | $2.0M | $76.1M | same sector · same stage |
| Medsource-Direct, Inc. | Pharmaceuticals | Seed | $2.0M | $74.6M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| DBV Technologies S.A. | Pharmaceuticals | Series D+ | $2.6B | 85% |
| PMV Pharmaceuticals, Inc. | Pharmaceuticals | Series C | $2.6B | 81% |
| Enumeral Biomedical Holdings, Inc. | Pharmaceuticals | Series B | $22.7M | 78% |
| BTB Therapeutics, Inc. | Pharmaceuticals | Seed | $7.9M | 78% |
| LP Investors, LLC | Pharmaceuticals | Series B | $1.4B | 78% |
| SapVax, LLC | Pharmaceuticals | Seed | $123.6M | 78% |
| Dauntless 1, Inc. | Pharmaceuticals | Series A | $247.8M | 78% |
| Juva Life, Inc. | Pharmaceuticals | Series A | $168.8M | 78% |
See where Bpv-1 Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Bpv-1 Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.